Applied Genetic Technologies Corporation (AGTC) and Axovant Sciences Ltd. (NASDAQ:AXON) Contrasting side by side

Since Applied Genetic Technologies Corporation (NASDAQ:AGTC) and Axovant Sciences Ltd. (NASDAQ:AXON) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Applied Genetic Technologies Corporation 28.99M 2.06 17.69M -1.08 0.00
Axovant Sciences Ltd. N/A 0.00 145.34M -1.53 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Applied Genetic Technologies Corporation and Axovant Sciences Ltd.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Applied Genetic Technologies Corporation and Axovant Sciences Ltd.

Net Margins Return on Equity Return on Assets
Applied Genetic Technologies Corporation -61.02% -19% -15.2%
Axovant Sciences Ltd. 0.00% -302.2% -119.2%

Volatility & Risk

A beta of 2.01 shows that Applied Genetic Technologies Corporation is 101.00% more volatile than Standard and Poor’s 500. Axovant Sciences Ltd. on the other hand, has 0.37 beta which makes it 63.00% less volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Applied Genetic Technologies Corporation are 4.3 and 4.3 respectively. Its competitor Axovant Sciences Ltd.’s Current Ratio is 2 and its Quick Ratio is 2. Applied Genetic Technologies Corporation can pay off short and long-term obligations better than Axovant Sciences Ltd.

Analyst Ratings

The Recommendations and Ratings for Applied Genetic Technologies Corporation and Axovant Sciences Ltd. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Applied Genetic Technologies Corporation 0 2 1 2.33
Axovant Sciences Ltd. 0 0 0 0.00

$5.33 is Applied Genetic Technologies Corporation’s average price target while its potential upside is 62.01%.

Insider & Institutional Ownership

Roughly 46.9% of Applied Genetic Technologies Corporation shares are held by institutional investors while 9.2% of Axovant Sciences Ltd. are owned by institutional investors. Applied Genetic Technologies Corporation’s share held by insiders are 0.3%. Insiders Comparatively, held 61.44% of Axovant Sciences Ltd. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Applied Genetic Technologies Corporation -4.93% -9.26% 43.49% 35.6% 60.26% 71.39%
Axovant Sciences Ltd. -31.49% -39.51% -40.95% -75.25% -75.3% -76.47%

For the past year Applied Genetic Technologies Corporation had bullish trend while Axovant Sciences Ltd. had bearish trend.

Summary

On 9 of the 10 factors Applied Genetic Technologies Corporation beats Axovant Sciences Ltd.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of AlzheimerÂ’s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.